2-Thiazolecarboxylicacid, 4-Bromo-

Incorporation of 4-bromo-2-thiazolecarboxylic acid into the backbone of direct-acting antiviral (DAA) NS5A inhibitors proceeds via a palladium-catalyzed Suzuki-Miyaura cross-coupling, a transformation whose impurity profile directly influences the mutagenic classification of the final API under ICH M7. The active pharmaceutical ingredient intermediate is manufactured in a 500–2000 L glass-lined reactor purged with nitrogen (O₂ < 500 ppm), where the bromothiazole acid (1.0 eq.) is coupled with an arylboronic acid pro-nucleophile (1.05–1.2 eq.) in a degassed THF/water (4:1) mixture containing K₂CO₃ (2.5 eq.). Catalysis relies on Pd(dppf)Cl₂·CH₂Cl₂ loaded at 0.8–1.2 mol%; the batch is heated to reflux (66–68°C) and held for 8–12 h until HPLC area% of the bromide starting material drops below 0.5%. Post-reaction work-up demands a scavenging sequence to meet ICH Q3D oral concentration limits: the cooled organic phase is washed with a 10 wt% aqueous N-acetyl-L-cysteine solution at 50°C, followed by a charcoal filtration through a 0.45 μm filter cartridge, reducing residual Pd to ≤ 2 ppm. Crystallization from isopropanol/water (3:1 v/v) with a controlled cooling ramp of −0.3°C/min yields an off-white crystalline solid that is dried at 55°C and 15 mbar for 16 h. The intermediate complies with a corporate specification of purity ≥ 99.6% (HPLC at 254 nm), any single unknown impurity ≤ 0.10%, and genotoxic impurity alert structures controlled to a threshold of toxicological concern of 1.5 μg/day according to a staged TTC approach. The resulting biphenyl-thiazole carboxylic acid scaffold is subsequently elaborated into an orally administered NS5A inhibitor drug substance formulated as a film-coated immediate-release tablet; the commercial form consistently meets the dissolution specification of ≥ 85% (Q) in 30 min using USP apparatus II at 75 rpm in 0.1 N HCl.

Can the Residual Palladium from Suzuki Coupling Compromise Oral Oncology Drug Safety Profiles?

In the synthesis of gefitinib- and osimertinib-analogue scaffolds where a thiazole-carboxamide replaces the classical quinazoline core, residual palladium from the key C–N bond-forming step presents a bioavailability risk that compels stringent elemental impurity controls. The process begins with an amidation between 4-bromo-2-thiazolecarboxylic acid and a substituted aniline bearing a sterically hindered primary amine. The carbodiimide-mediated coupling uses EDC·HCl (1.15 eq.) and HOBt monohydrate (1.20 eq.) in anhydrous DMF at 0–5°C during the activation phase, after which the amine (0.95 eq.) is introduced and the mixture is warmed to 22–25°C for 18 h. Conversion is monitored by TLC (silica gel 60 F₂₅₄, eluent ethyl acetate/heptane 7:3); yield after aqueous work-up and tert-butyl methyl ether trituration reaches 87–92%. The subsequent Buchwald-Hartwig cross-coupling to install a morpholino or piperazinyl pharmacophore onto a secondary aryl halide employs XPhos Pd G3 pre-catalyst at an ultra-low loading of 0.1 mol% in toluene at 105°C for 2 h. Despite this minimal catalyst charge, residual Pd in the isolated crude amide intermediate typically ranges 12–40 ppm, far exceeding the 10 ppm concentration limit for an oral drug substance with a 100 mg/day dose as derived from ICH Q3D Table A.2.2. A dedicated metal scavenging campaign is therefore inserted: the crude toluene stream is contacted with 3.0 wt% of a macroporous polystyrene-bound trimercaptotriazine resin in a jacketed column at 60°C with a residence time of 4–6 min, followed by a polish filtration through a 0.2 μm PTFE membrane. Lot-to-lot Pd residuals after scavenging fall to 0.3–1.8 ppm. Crystallization from acetonitrile/water (2:1) with DMSO solvate control yields the final intermediate as a non-solvated polymorph, confirmed by XRPD. The finished oncology drug product is a methanesulfonate salt encapsulated in a hypromellose capsule, requiring a labeled storage condition of ≤ 30°C and ≤ 65% RH per ICH stability zone II.

Field-Ready Emulsifiable Concentrate Formulations for Succinate Dehydrogenase Inhibition

Manufacturing flowable SDHI fungicide intermediates from 4-bromo-2-thiazolecarboxylic acid begins with quantitative conversion to the acid chloride, a step notorious for generating exothermic runaway scenarios when thionyl chloride dosage exceeds 1.7 molar equivalents under adiabatic conditions. In a 3000 L enameled reactor equipped with a reflux condenser and a caustic scrubber (NaOH 20 wt%), the carboxylic acid (1.0 kmol) is suspended in toluene (4.0 L/kg) along with DMF (0.02 eq.) as a nucleophilic catalyst. Thionyl chloride (1.45 eq.) is dosed via a mass flow meter at a rate that maintains the internal temperature at 58–62°C; the addition typically requires 2.5 h. After 1 h of post-reaction stirring, vacuum distillation (80 mbar, jacket 75°C) strips excess SOCl₂ and toluene to leave a dark-brown acyl chloride oil that solidifies below 45°C. This crude acyl chloride is dissolved in dry THF (2.0 L/kg) and added over 90 min to a pre-chilled (−5 to 0°C) mixture of a substituted 2-aminothiazole (1.03 eq.) and triethylamine (2.2 eq.) in THF. The exothermic amidation is controlled by jacket temperature ramping to 20°C; HPLC analysis after 3 h confirms ≤ 0.8% residual amine. The precipitated triethylammonium chloride is removed by centrifugation, and the organic stream is washed with water (pH 6.5–7.0) followed by brine. Solvent displacement into ethanol/water (1:1) induces crystallization; the wet cake is dried in a fluidized bed dryer with an inlet air temperature of 85°C and exhaust monitoring for residual ethanol (< 500 ppm). The resulting secondary intermediate is a key building block for pyrazole-4-carboxamide SDHI actives registered under FAO specifications. Its formulated end-use product is a 200 g/L suspension concentrate (SC) with a particle size D₅₀ of 1.2 μm (Malvern wet dispersion) and an oil-in-water emulsion stability lasting ≥ 24 h according to CIPAC MT 36. Registration for the European market requires compliance with Regulation EC 1107/2009 and a residue definition compliant with Regulation (EU) 2019/88; the technical concentrate must demonstrate a 6-month accelerated storage stability at 54°C with degradation ≤ 5%.

Fluorescent intercalating dyes based on asymmetric cyanine architectures derive their photostability and DNA-binding affinity from the electron-deficient thiazole moiety; here, 4-bromo-2-thiazolecarboxylic acid serves as the electrophilic trap during one-pot condensation with 2-methylthioquinolinium salts under strictly anhydrous methanol to prevent carbinol pseudobase formation. The reaction is charged under argon in a borosilicate jacketed vessel: thiazole acid (1.00 eq.), N-alkyl-2-methylthioquinolinium iodide (1.15 eq.), and powdered anhydrous K₂CO₃ (2.5 eq.) are refluxed (65°C) for 4.5 h with exclusion of light. The crude dye is purified by flash chromatography on triethylamine-deactivated silica (dichloromethane/methanol/acetic acid 80:18:2), and the product fraction is dried to a lyophilized dark-red powder with a molar extinction coefficient ε of 78 000 M⁻¹cm⁻¹ at 528 nm in TE buffer. For diagnostic kit formulation, the dye is re-constituted in anhydrous DMSO to a stock concentration of 10 mM and stored at −20°C under argon in single-use aliquots to avoid repeated freeze-thaw cycles that promote aggregation. The labeling protocol adds the succinimidyl ester derivative of the dye to oligonucleotides at a 15-fold molar excess in 0.1 M carbonate buffer (pH 8.5) for 4 h at 25°C, followed by HPLC purification (C18, gradient 5–40% acetonitrile in 0.1 M TEAA) to separate the unreacted probe. Finished conjugate must meet an absorbance ratio A₂₆₀/A₅₂₈ of 0.18–0.22 to guarantee a dye-to-oligonucleotide ratio of 1.0 ± 0.05. The assembled qPCR master mix incorporating this probe is validated for in vitro diagnostic use under ISO 13485:2016 and complies with the restriction of hazardous substances under RoHS Directive 2011/65/EU for photoelectric components. End-use products include lyophilized beads for respiratory pathogen panel detection and liquid-stable single-plex assays for SARS-CoV-2 E-gene quantification.

When Lipophilic Cationic Moiety Conjugates Require Strict Redox Potential Tuning

To achieve site-specific accumulation of antioxidants within the inner mitochondrial membrane, the triphenylphosphonium (TPP+) delivery vector must be attached to a redox-active aromatic core through an alkyl spacer whose length dictates the depth of penetration into the lipid bilayer. The 4-bromo-2-thiazolecarboxylic acid scaffold is first protected as its methyl ester by refluxing in methanolic HCl generated from acetyl chloride (1.3 eq.) at 65°C for 3 h; evaporation and hexane trituration give the methyl ester in 96–98% yield with 99% purity. This ester subsequently participates in a palladium-catalyzed Negishi coupling with an alkylzinc reagent prepared in situ from ω-bromoalkanoate ethyl ester and Rieke zinc (activated zinc powder, 1.5 eq.). Catalyst Pd(dba)₂ (1.5 mol%) and electron-rich biaryl phosphine ligand SPhos (3.0 mol%) are combined in a glovebox (O₂ < 0.5 ppm, H₂O < 0.5 ppm) and the reaction is heated to 50°C for 16 h. Quenching with 1 M HCl hydrolyzes both the zincate and the thiazole methyl ester, liberating the free acid intermediate. After extractive work-up, the ω-(2-carboxy-thiazol-4-yl)alkanoic acid is coupled with (3-hydroxypropyl)triphenylphosphonium bromide via DCC/DMAP in dichloromethane, giving the final mitochondrial-targeting conjugate. Critical process controls center on the redox potential of the thiazole intermediate; cyclic voltammetry in acetonitrile (0.1 M TBAPF₆) must show a reduction wave at −1.28 ± 0.02 V vs. Ag/AgCl to maintain TPP+ conjugate stability. Any deviation beyond ± 0.03 V indicates over-reduction of the thiazole ring and mandates a column repurification using Sephadex LH-20 with methanol. The sterile-filtered API solution is filled into amber vials and lyophilized with mannitol as a cryoprotectant to yield a freeze-dried powder for reconstitution. The terminal medicine, an injectable cardioprotective agent under preclinical evaluation, must satisfy the battery of safety pharmacology core tests described in ICH S7A and the thorough QT/QTc study outlined in ICH E14, with a cardiac ion channel panel assay demonstrating an IC₅₀ > 30 μM against hERG.

Band Gap Engineering at the Donor-Acceptor Interface via Thiazole Electron-Withdrawing Monomers

Achieving a power conversion efficiency exceeding 12% in non-fullerene organic solar cells hinges on the precise control of the highest occupied molecular orbital (HOMO) energy level of the donor polymer relative to the acceptor’s LUMO. 4-Bromo-2-thiazolecarboxylic acid is converted to its 2-ethylhexyl ester via esterification with 2-ethylhexanol (5.0 eq.) under Dean-Stark conditions catalyzed by p-toluenesulfonic acid (0.1 eq.) at 130°C for 6 h, after which distillation removes excess alcohol. The resulting 2-ethylhexyl 4-bromo-2-thiazolecarboxylate monomer (1.000 eq.) undergoes Stille polycondensation with 5,5′-bis(trimethylstannyl)-2,2′-bithiophene (1.000 eq.) in anhydrous chlorobenzene (0.15 M) employing Pd₂(dba)₃ (2 mol%) and P(o-tol)₃ (8 mol%). The reaction mixture is subjected to three freeze-pump-thaw cycles and sealed in a Schlenk tube under argon, then heated in an oil bath at 120°C for 36 h. End-capping is performed sequentially with 2-bromothiophene (0.1 eq., 1 h) and 2-(tributylstannyl)thiophene (0.1 eq., 1 h) to remove reactive chain ends that would otherwise cause irreversible oxidation. The polymer is precipitated into acidified methanol and purified by successive Soxhlet extraction with methanol (24 h), acetone (12 h), hexane (12 h), and finally chloroform. The chloroform fraction, concentrated under reduced pressure, exhibits a number-average molecular weight (Mₙ) of 35–48 kg/mol and a dispersity Đ of 1.2–1.4 via high-temperature GPC at 150°C in 1,2,4-trichlorobenzene. Spin-coating from 10 mg/mL chlorobenzene solution onto ITO/PEDOT:PSS substrates followed by thermal annealing at 140°C for 10 min produces a bulk heterojunction active layer. The finished device integrates a ZnO electron-transport layer and a MoOₓ hole-transport layer, all encapsulated with a UV-curable epoxy under a glass lid to achieve a T₈₀ lifetime of ≥ 2000 h under continuous simulated AM 1.5G illumination at 65°C. Material certification for consumer electronics markets requires compliance with the RoHS 2.0 directive and the IEC 61215:2021 qualification standard for terrestrial photovoltaic modules, including a damp-heat test at 85°C/85% RH for 1000 h with less than 5% efficiency degradation.